Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000624583 | SCV000742823 | likely pathogenic | Inborn genetic diseases | 2019-10-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001057694 | SCV001222198 | pathogenic | Mucopolysaccharidosis, MPS-IV-B; GM1 gangliosidosis | 2023-09-21 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 49 of the GLB1 protein (p.Arg49His). This variant is present in population databases (rs780523881, gnomAD 0.01%). This missense change has been observed in individual(s) with GM1-gangliosidosis (PMID: 15986423, 30267299). ClinVar contains an entry for this variant (Variation ID: 521991). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GLB1 protein function. Experimental studies have shown that this missense change affects GLB1 function (PMID: 20175788). |
Gene |
RCV003238787 | SCV003936369 | pathogenic | not provided | 2023-06-29 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a significant reduction in enzyme activity compared to wildtype (Hofer et al., 2010); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 20175788, 30267299, 15986423) |
Counsyl | RCV000672724 | SCV000797858 | uncertain significance | GM1 gangliosidosis type 2; GM1 gangliosidosis type 3; Mucopolysaccharidosis, MPS-IV-B; Infantile GM1 gangliosidosis | 2018-02-13 | flagged submission | clinical testing |